Jesse Richards
Overview
Explore the profile of Jesse Richards including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
39
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Heymsfield S, Clement K, Dubern B, Goldstone A, Haqq A, Kuhnen P, et al.
Curr Obes Rep
. 2025 Mar;
14(1):23.
PMID: 40067578
No abstract available.
2.
Heymsfield S, Clement K, Dubern B, Goldstone A, Haqq A, Kuhnen P, et al.
Curr Obes Rep
. 2025 Jan;
14(1):13.
PMID: 39856371
Purpose Of Review: Hyperphagia is a condition associated with rare obesity-related diseases, presenting as a pathologic, insatiable hunger accompanied by abnormal food-seeking behaviors. In October 2023, a group of researchers...
3.
Richards J, Dorand M, Paszkowiak M, Ahmed S, McCorkle C, Kathuria P
Obes Pillars
. 2025 Jan;
13():100155.
PMID: 39801599
Background: Kinase D-interacting substrate of 220 kDa ("KIDINS220") is an integral plasma membrane protein essential to signaling throughout the body; abnormalities are linked to a variety of disorders, including obesity,...
4.
Almandoz J, Wadden T, Tewksbury C, Apovian C, Fitch A, Ard J, et al.
Obesity (Silver Spring)
. 2024 Dec;
33(1):9-11.
PMID: 39675924
No abstract available.
5.
Almandoz J, Wadden T, Tewksbury C, Apovian C, Fitch A, Ard J, et al.
Obesity (Silver Spring)
. 2024 Oct;
32(11):1982-1984.
PMID: 39363483
No abstract available.
6.
Esparham A, Mehri A, Dalili A, Richards J, Khorgami Z
Obes Rev
. 2024 Aug;
25(11):e13811.
PMID: 39134066
Introduction: Weight regain and insufficient weight loss are major challenges after metabolic bariatric surgery (MBS), affecting patients' comorbidities and quality of life. The current systematic review and meta-analysis aim to...
7.
Almandoz J, Wadden T, Tewksbury C, Apovian C, Fitch A, Ard J, et al.
Obesity (Silver Spring)
. 2024 Jun;
32(9):1613-1631.
PMID: 38853526
The improved efficacy and generally favorable safety profile of recently approved and emerging antiobesity medications (AOMs), which result in an average weight reduction of ≥15%, represent significant advancement in the...
8.
Paszkowiak M, Dorand M, Richards J
Obes Pillars
. 2023 Nov;
5:100059.
PMID: 37990741
Background: Once thought to be primarily a result of lifestyle, it is now known that obesity has significant genetic components. Dozens of genes have been linked to obesity, and office-based...
9.
Richards J, Bang N, Ratliff E, Paszkowiak M, Khorgami Z, Khalsa S, et al.
Obes Pillars
. 2023 Nov;
7:100080.
PMID: 37990682
Objective: Binge eating disorder (BED) is the most common eating disorder, and yet only one pharmacotherapy (lisdexamfetamine), which has known abuse-potential, is FDA-approved. Topiramate is also commonly prescribed off-label for...
10.
Bays H, Burridge K, Richards J, Fitch A
Obes Pillars
. 2023 Nov;
4:100039.
PMID: 37990661
Background: Historically, many anti-obesity medications (AOMs) were withdrawn from development and/or the market due to safety concerns. Another challenge was that, with some exceptions, most of these AOMs had limited...